sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol.
|
(-)-erythro-fluorocitrate
|
1,3-difluoro-2-propanol
|
NONE
|
11170315.xml
|
DDI-MedLine.d125.s4
|
DDI-MedLine.d125.s4.p2
|
Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.
|
Fluconazole
|
fluconazole
|
NONE
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s16
|
DDI-DrugBank.d172.s16.p0
|
However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
|
ibuprofen
|
coumarin-type anticoagulants
|
EFFECT
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s1
|
DDI-DrugBank.d415.s1.p1
|
However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.
|
azithromycin
|
warfarin
|
ADVISE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s4
|
DDI-DrugBank.d53.s4.p0
|
Warfarin Keppra (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin.
|
Warfarin
|
R warfarin
|
NONE
|
Levetiracetam_ddi.xml
|
DDI-DrugBank.d212.s19
|
DDI-DrugBank.d212.s19.p1
|
Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
|
diclofenac
|
aspirin
|
ADVISE
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s0
|
DDI-DrugBank.d249.s0.p4
|
Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
|
anileridine
|
sedatives
|
ADVISE
|
Anileridine_ddi.xml
|
DDI-DrugBank.d215.s0
|
DDI-DrugBank.d215.s0.p1
|
In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval.
|
olanzapine
|
risperidone
|
NONE
|
11217867.xml
|
DDI-MedLine.d83.s11
|
DDI-MedLine.d83.s11.p1
|
Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
|
alosetron
|
voriconazole
|
ADVISE
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s10
|
DDI-DrugBank.d364.s10.p3
|
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
|
Nabilone
|
narcotic analgesics
|
ADVISE
|
Nabilone_ddi.xml
|
DDI-DrugBank.d552.s0
|
DDI-DrugBank.d552.s0.p4
|
Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7
|
Steroids
|
edetate calcium disodium
|
EFFECT
|
Edetic Acid_ddi.xml
|
DDI-DrugBank.d191.s1
|
DDI-DrugBank.d191.s1.p0
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
barbiturates
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p4
|
Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
|
acetaminophen
|
furosemide
|
NONE
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s2
|
DDI-DrugBank.d75.s2.p13
|
On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms).
|
naloxone
|
morphine
|
EFFECT
|
3155550.xml
|
DDI-MedLine.d63.s5
|
DDI-MedLine.d63.s5.p0
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
amiodarone
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p1
|
Dexfenfluramine should not be administered with other serotoninergic agents.
|
Dexfenfluramine
|
serotoninergic agents
|
ADVISE
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s6
|
DDI-DrugBank.d423.s6.p0
|
propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were 20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.
|
propranolol
|
propranolol
|
NONE
|
Isradipine_ddi.xml
|
DDI-DrugBank.d81.s6
|
DDI-DrugBank.d81.s6.p7
|
Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.
|
warfarin
|
NSAIDs
|
INT
|
Nabumetone_ddi.xml
|
DDI-DrugBank.d174.s1
|
DDI-DrugBank.d174.s1.p2
|
Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..
|
thiazide diuretics
|
allopurinol
|
ADVISE
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s15
|
DDI-DrugBank.d413.s15.p0
|
Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or
|
Sulfapyridine
|
Acetaminophen
|
INT
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s1
|
DDI-DrugBank.d179.s1.p0
|
Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
|
antacids
|
vitamin D
|
ADVISE
|
Calcitriol_ddi.xml
|
DDI-DrugBank.d384.s15
|
DDI-DrugBank.d384.s15.p5
|
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
probenecid
|
beta adrenergic blocking agents
|
NONE
|
Glibenclamide_ddi.xml
|
DDI-DrugBank.d178.s0
|
DDI-DrugBank.d178.s0.p32
|
Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.
|
phenytoin
|
dexamethasone
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s27
|
DDI-DrugBank.d314.s27.p2
|
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
|
Magnesium
|
FACTIVE
|
ADVISE
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s7
|
DDI-DrugBank.d347.s7.p8
|
While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
|
bupropion
|
phenobarbital
|
MECHANISM
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s8
|
DDI-DrugBank.d5.s8.p1
|
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.
|
rifampin
|
warfarin
|
EFFECT
|
1115445.xml
|
DDI-MedLine.d116.s6
|
DDI-MedLine.d116.s6.p0
|
Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .
|
dyphylline
|
probenecid
|
MECHANISM
|
Dyphylline_ddi.xml
|
DDI-DrugBank.d4.s2
|
DDI-DrugBank.d4.s2.p0
|
Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
|
sulfonamides
|
penicillins
|
EFFECT
|
Ampicillin_ddi.xml
|
DDI-DrugBank.d211.s2
|
DDI-DrugBank.d211.s2.p13
|
Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
|
erythromycin
|
cyclosporine
|
INT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s24
|
DDI-DrugBank.d522.s24.p0
|
Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
|
neomycin
|
5-fluorouracil
|
MECHANISM
|
Neomycin_ddi.xml
|
DDI-DrugBank.d330.s2
|
DDI-DrugBank.d330.s2.p3
|
The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.
|
terfenadine
|
dirithromycin
|
EFFECT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s7
|
DDI-DrugBank.d522.s7.p2
|
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
fluvoxamine
|
5-HT1 agonists
|
EFFECT
|
Frovatriptan_ddi.xml
|
DDI-DrugBank.d426.s3
|
DDI-DrugBank.d426.s3.p17
|
The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.
|
MAO inhibitors
|
hydrocodone
|
EFFECT
|
Hydrocodone_ddi.xml
|
DDI-DrugBank.d396.s2
|
DDI-DrugBank.d396.s2.p1
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Norvir
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p29
|
ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.
|
ROMAZICON
|
benzodiazepines
|
EFFECT
|
Flumazenil_ddi.xml
|
DDI-DrugBank.d234.s5
|
DDI-DrugBank.d234.s5.p0
|
Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.
|
magnesium hydroxide
|
antacid
|
NONE
|
Capecitabine_ddi.xml
|
DDI-DrugBank.d88.s0
|
DDI-DrugBank.d88.s0.p9
|
In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.
|
cimetidine
|
tricyclic antidepressants
|
MECHANISM
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s3
|
DDI-DrugBank.d202.s3.p0
|
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
|
cimetidine
|
iodamide
|
MECHANISM
|
7756965.xml
|
DDI-MedLine.d68.s0
|
DDI-MedLine.d68.s0.p13
|
Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary
|
hydroxyurea
|
uricosuric medication
|
EFFECT
|
Hydroxyurea_ddi.xml
|
DDI-DrugBank.d16.s2
|
DDI-DrugBank.d16.s2.p0
|
Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
|
ampicillin
|
ampicillin
|
NONE
|
Ampicillin_ddi.xml
|
DDI-DrugBank.d211.s5
|
DDI-DrugBank.d211.s5.p2
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
fluphenazine
|
Stelazine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p124
|
Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.
|
COREG
|
diltiazem
|
EFFECT
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s16
|
DDI-DrugBank.d269.s16.p2
|
Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
|
hydroxychloroquine
|
heparin sodium
|
EFFECT
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s2
|
DDI-DrugBank.d488.s2.p35
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
quinolones
|
multivitamins
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p6
|
Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
|
Aprepitant
|
clarithromycin
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s31
|
DDI-DrugBank.d382.s31.p4
|
In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.
|
Vardenafil
|
tamsulosin
|
EFFECT
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s32
|
DDI-DrugBank.d198.s32.p2
|
Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
|
Clonidine
|
barbiturates
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s2
|
DDI-DrugBank.d495.s2.p10
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
|
norepinephrine
|
tricyclic antidepressants
|
EFFECT
|
Chloroprocaine_ddi.xml
|
DDI-DrugBank.d110.s0
|
DDI-DrugBank.d110.s0.p10
|
Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.
|
Chlorpromazine
|
amphetamines
|
EFFECT
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s12
|
DDI-DrugBank.d158.s12.p3
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
Phenytoin
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p31
|
Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
|
Codeine
|
CNS depressants
|
EFFECT
|
Codeine_ddi.xml
|
DDI-DrugBank.d464.s0
|
DDI-DrugBank.d464.s0.p5
|
Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).
|
danazol
|
lovastatin
|
EFFECT
|
Lovastatin_ddi.xml
|
DDI-DrugBank.d567.s11
|
DDI-DrugBank.d567.s11.p2
|
Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
|
Warfarin
|
cefixime
|
EFFECT
|
Cefixime_ddi.xml
|
DDI-DrugBank.d339.s2
|
DDI-DrugBank.d339.s2.p1
|
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
|
Fluconazole
|
carbamazepine
|
NONE
|
Delavirdine_ddi.xml
|
DDI-DrugBank.d251.s0
|
DDI-DrugBank.d251.s0.p20
|
Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.
|
rifampin
|
VIRACEPT
|
MECHANISM
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s32
|
DDI-DrugBank.d340.s32.p3
|
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
|
phenothiazines
|
estrogens
|
NONE
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s4
|
DDI-DrugBank.d245.s4.p27
|
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
nonsteroidal anti-inflammatory agents
|
salicylates
|
NONE
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s0
|
DDI-DrugBank.d245.s0.p8
|
However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.
|
Acarbose
|
metformin
|
MECHANISM
|
Acarbose_ddi.xml
|
DDI-DrugBank.d536.s10
|
DDI-DrugBank.d536.s10.p2
|
Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.
|
cimetidine
|
tricyclic antidepressants
|
MECHANISM
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s26
|
DDI-DrugBank.d386.s26.p0
|
Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.
|
contraceptives
|
nevirapine
|
ADVISE
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s26
|
DDI-DrugBank.d270.s26.p0
|
Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
|
Lithium
|
ACE inhibitors
|
NONE
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s16
|
DDI-DrugBank.d107.s16.p2
|
Therefore, the combined use of lovastatin with fibrates should generally be avoided.
|
lovastatin
|
fibrates
|
ADVISE
|
Clofibrate_ddi.xml
|
DDI-DrugBank.d12.s9
|
DDI-DrugBank.d12.s9.p0
|
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
paroxetine
|
5-HT1 agonists
|
EFFECT
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s6
|
DDI-DrugBank.d299.s6.p26
|
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
|
alcohol
|
monoamine oxidase (MAO) inhibitors
|
NONE
|
Brompheniramine_ddi.xml
|
DDI-DrugBank.d192.s0
|
DDI-DrugBank.d192.s0.p12
|
Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
|
Sumatriptan
|
SSRI
|
NONE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s16
|
DDI-DrugBank.d568.s16.p1
|
The effect of BREVIBLOC on the duration of succinylcholine-induced neuromuscular blockade was studied in patients undergoing surgery.
|
BREVIBLOC
|
succinylcholine
|
NONE
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s8
|
DDI-DrugBank.d422.s8.p0
|
It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.
|
buspirone hydrochloride
|
MAO inhibitors
|
ADVISE
|
Buspirone_ddi.xml
|
DDI-DrugBank.d463.s0
|
DDI-DrugBank.d463.s0.p0
|
Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.
|
diuretics
|
enalaprilat
|
EFFECT
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s0
|
DDI-DrugBank.d107.s0.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
amiodarone
|
sulindac
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p253
|
Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
|
butyrophenones
|
epinephrine
|
EFFECT
|
Bupivacaine_ddi.xml
|
DDI-DrugBank.d153.s4
|
DDI-DrugBank.d153.s4.p2
|
Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
|
amphotericin B
|
skeletal muscle relaxants
|
EFFECT
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s12
|
DDI-DrugBank.d318.s12.p3
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
acetaminophen
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p15
|
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.
|
L-tyrosine
|
MAO inhibitors
|
EFFECT
|
L-Tyrosine_ddi.xml
|
DDI-DrugBank.d111.s0
|
DDI-DrugBank.d111.s0.p14
|
Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.
|
acebutolol
|
catecholamine depletors
|
ADVISE
|
Acebutolol_ddi.xml
|
DDI-DrugBank.d388.s1
|
DDI-DrugBank.d388.s1.p0
|
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
|
Dexbrompheniramine
|
anticholinergics
|
EFFECT
|
Brompheniramine_ddi.xml
|
DDI-DrugBank.d192.s0
|
DDI-DrugBank.d192.s0.p3
|
This indicates that gabapentin does not undergo renal tubular secretion by the pathway that is blocked by probenecid.
|
gabapentin
|
probenecid
|
NONE
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s42
|
DDI-DrugBank.d438.s42.p0
|
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
|
phencyclidine
|
PCP
|
NONE
|
3968644.xml
|
DDI-MedLine.d30.s1
|
DDI-MedLine.d30.s1.p5
|
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
|
Lithium
|
ACE inhibitors
|
NONE
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s6
|
DDI-DrugBank.d176.s6.p2
|
A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;
|
ethacrynic acid
|
warfarin
|
MECHANISM
|
Ethacrynic acid_ddi.xml
|
DDI-DrugBank.d414.s4
|
DDI-DrugBank.d414.s4.p0
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
methotrexate
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p23
|
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
|
ouabain
|
ketamine
|
EFFECT
|
1167743.xml
|
DDI-MedLine.d23.s2
|
DDI-MedLine.d23.s2.p1
|
The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
|
Robinul
|
anticholinergics
|
EFFECT
|
Glycopyrrolate_ddi.xml
|
DDI-DrugBank.d510.s0
|
DDI-DrugBank.d510.s0.p0
|
Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON.
|
rifampin
|
MEPRON
|
ADVISE
|
Atovaquone_ddi.xml
|
DDI-DrugBank.d424.s4
|
DDI-DrugBank.d424.s4.p0
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
anticoagulants
|
corticosteroids
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p12
|
Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.
|
bosentan
|
ketoconazole
|
MECHANISM
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s23
|
DDI-DrugBank.d289.s23.p3
|
Even though such interactions have not been seen in clinical studies with DynaCirc (isradipine), an increased volume of circulating fluids might be required if such an interaction were to occur.
|
DynaCirc
|
isradipine
|
NONE
|
Isradipine_ddi.xml
|
DDI-DrugBank.d81.s15
|
DDI-DrugBank.d81.s15.p0
|
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylurea
|
salicylates
|
EFFECT
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s0
|
DDI-DrugBank.d245.s0.p1
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
Tylenol
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p1
|
In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steadystate trough (Cmin) phenytoin plasma concentration was 17 5 micrograms/mL.
|
phenytoin
|
phenytoin
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s12
|
DDI-DrugBank.d434.s12.p0
|
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.
|
hydrochlorothiazide
|
phenobarbital
|
NONE
|
Losartan_ddi.xml
|
DDI-DrugBank.d30.s0
|
DDI-DrugBank.d30.s0.p3
|
Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.
|
cyclosporine
|
corticosteroids
|
EFFECT
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s11
|
DDI-DrugBank.d314.s11.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
nalidixic acid
|
quinine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1242
|
Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected.
|
Coumarin Anticoagulant
|
warfarin
|
NONE
|
Lovastatin_ddi.xml
|
DDI-DrugBank.d567.s13
|
DDI-DrugBank.d567.s13.p1
|
SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.
|
SUSTIVA
|
ketoconazole
|
MECHANISM
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s79
|
DDI-DrugBank.d531.s79.p1
|
In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.
|
rifampin
|
haloperidol
|
MECHANISM
|
Haloperidol_ddi.xml
|
DDI-DrugBank.d186.s5
|
DDI-DrugBank.d186.s5.p5
|
Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.
|
diltiazem
|
cimetidine
|
ADVISE
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s15
|
DDI-DrugBank.d565.s15.p0
|
Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
|
anti-depressants
|
lithium
|
NONE
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s1
|
DDI-DrugBank.d86.s1.p9
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
opioids
|
alcohol
|
NONE
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p49
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Lipitor
|
clofibrate
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p639
|
Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.
|
Atromid-S
|
tolbutamide
|
MECHANISM
|
Clofibrate_ddi.xml
|
DDI-DrugBank.d12.s3
|
DDI-DrugBank.d12.s3.p1
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.